CIP
NVO

Capital Insight Partners’s Novo Nordisk NVO Stock Holding History

Capital Insight Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,033
Closed -$663K – 76
2025
Q4 		$663K Sell
13,033
-31,324
-71% -$1.6M 0.14% 96
2025
Q3 		$2.46M Sell
44,357
-6,248
-12% -$366K 0.41% 66
2025
Q2 		$3.49M Sell
50,605
-4,702
-9% -$320K 0.61% 54
2025
Q1 		$3.84M Buy
55,307
+3,095
+6% +$256K 0.67% 49
2024
Q4 		$4.49M Buy
52,212
+6,008
+13% +$650K 0.78% 46
2024
Q3 		$5.5M Buy
46,204
+1,929
+4% +$257K 0.96% 33
2024
Q2 		$6.32M Sell
44,275
-1,129
-2% -$150K 1.19% 24
2024
Q1 		$5.83M Buy
45,404
+674
+2% +$80.2K 1.09% 25
2023
Q4 		$4.63M Buy
44,730
+518
+1% +$51.2K 0.95% 31
2023
Q3 		$4.02M Buy
44,212
+2,038
+5% +$180K 0.91% 34
2023
Q2 		$3.41M Sell
42,174
-412
-1% -$33.7K 0.76% 43
2023
Q1 		$3.39M Buy
42,586
+1,096
+3% +$77.7K 0.8% 41
2022
Q4 		$2.81M Buy
41,490
+342
+0.8% +$20.1K 0.73% 44
2022
Q3 		$2.05M Buy
41,148
+1,722
+4% +$92.2K 0.55% 63
2022
Q2 		$2.2M Sell
39,426
-166
-0.4% -$9.21K 0.51% 64
2022
Q1 		$2.2M Sell
39,592
-1,598
-4% -$82K 0.45% 77
2021
Q4 		$2.31M Buy
41,190
+2,048
+5% +$111K 0.47% 75
2021
Q3 		$1.88M Buy
39,142
+1,290
+3% +$62.4K 0.41% 93
2021
Q2 		$1.58M Buy
37,852
+1,710
+5% +$66.3K 0.36% 95
2021
Q1 		$1.22M Buy
36,142
+890
+3% +$31.7K 0.3% 108
2020
Q4 		$1.23M Buy
35,252
+426
+1% +$14.7K 0.31% 104
2020
Q3 		$1.21M Sell
34,826
-598
-2% -$19.9K 0.34% 102
2020
Q2 		$1.16M Sell
35,424
-156
-0.4% -$4.98K 0.37% 93
2020
Q1 		$1.07M Buy
35,580
+1,790
+5% +$53.3K 0.57% 61
2019
Q4 		$978K Sell
33,790
-52
-0.2% -$1.44K 0.45% 68
2019
Q3 		$875K Sell
33,842
-256
-0.8% -$6.47K 0.76% 58
2019
Q2 		$870K Buy
34,098
+570
+2% +$14.1K 0.76% 60
2019
Q1 		$877K Buy
33,528
+304
+0.9% +$7.47K 0.79% 56
2018
Q4 		$765K Buy
+33,224
New +$738K 0.79% 50

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Capital Insight Partners's NVO Position: Q1 2026 in Review

Capital Insight Partners sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 13,033 shares — an estimated $663K sold.

Capital Insight Partners first reported a position in NVO in Q4 2018 and held it in 29 quarters. The position peaked at $6.32M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Capital Insight Partners reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Capital Insight Partners sold 13,033 Novo Nordisk shares in Q1 2026, an estimated $663K.
  • Capital Insight Partners first reported a position in Novo Nordisk in Q4 2018 and held it in 29 quarters.
  • Capital Insight Partners's Novo Nordisk position peaked at $6.32M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Capital Insight Partners's 13F filing for Q1 2026.